

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors

Information for the public

Published: 28 April 2026

www.nice.org.uk

Ripretinib (Qinlock) is available on the NHS as a possible treatment for advanced gastrointestinal stromal tumours after at least 3 kinase inhibitors (including imatinib) in adults.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on soft tissue sarcoma](#) may be a good place to find out more.

These organisations can give you advice and support:

- [PAWS-GIST](#), info@pawsgistclinic.org.uk
- [GIST Cancer UK](#), 0300 400 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9444-1